



FOR IMMEDIATE RELEASE

CONTACT

XXXXX
XXXX
(XXX) XXX-XXX

**Calixa Therapeutics Announces Promising Phase 1 Results for CXA-101,
A Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-pseudomonal Activity**

SAN DIEGO, Jan XX, 2009 – Calixa Therapeutics, Inc. (www.calixainc.com) today announced positive results from a Phase 1 trial of intravenous CXA-101, a novel cephalosporin antibiotic with excellent *in vitro* anti-pseudomonal activity. The completed Phase 1 trial was designed as a single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetic profile of the compound in healthy volunteers. The study was successfully conducted in the US under an IND. The results from this first Phase 1 trial demonstrated that CXA-101 was well tolerated, with a clinical and laboratory safety profile similar to that of marketed cephalosporin antibiotics. No dose-limiting toxicity was observed, even at the highest dose regimen evaluated. In addition, CXA-101 demonstrated predictable, linear pharmacokinetics after intravenous administration in humans. The results of this study fully support the further clinical development of this compound.

Calixa acquired the global development rights to CXA-101 (FR205264) from Astellas Pharma Inc in 2008. CXA-101's potent *in vitro* activity against *Pseudomonas aeruginosa* has the potential to address the unmet medical need posed by this very problematic gram-negative pathogen, which is a common cause of serious health-care associated infection associated with high morbidity and mortality. Nonclinical studies have shown CXA-101 is highly active against multiple drug-resistant *Pseudomonas aeruginosa*, including many strains resistant to carbapenems, an antibiotic class generally considered as having the most potent activity against resistant gram-negative pathogens.

"*Pseudomonas aeruginosa* is usually less susceptible to commonly used antibiotics, and infections caused by this organism are often severe and very difficult to treat. There is a major unmet medical need for a safe and efficacious antibiotic to treat pseudomonal infections. Unfortunately, the pipeline for such drugs is virtually empty" said XXX, XX., XXXX of Calixa. "We were very pleased to see the promising results that will enable us to quickly move CXA-101 into Phase 2 to validate its efficacy and safety in patients."

"I am very excited about the outcome of this trial. Our development program is progressing well, led by an experienced team with a track record of success in the anti-infective field," added Eckard Weber, M.D., CEO and President of Calixa Therapeutics, Inc. "These Phase 1 data suggest a well-tolerated drug with an excellent profile for potential clinical use as treatment of gram-negative bacterial infections."

About Calixa Therapeutics, Inc

Calixa Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of infectious diseases. The Company's initial focus is on developing novel antibiotics to be used in the hospital setting. Calixa, which is privately held, is headquartered in San Diego, California, with operations in the San Francisco Bay Area. For additional information, please visit: www.calixainc.com.

- END -